Roy­al­ty Phar­ma's mile­stone pay­ment to Ar­row­head; Abeon­a's $75M of­fer­ing

Plus, news about Soleno, No­vo Nordisk and Car­dior Phar­ma­ceu­ti­cals:

Roy­al­ty Phar­ma pays Ar­row­head Phar­ma­ceu­ti­cals: The $50 mil­lion mile­stone pay­ment comes af­ter the com­plet­ed en­roll­ment of a Phase 3 tri­al in­ves­ti­gat­ing ol­pasir­an in pa­tients with ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease and el­e­vat­ed lipopro­tein. Ar­row­head could still get an­oth­er $485 mil­lion in mile­stone pay­ments for the drug. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER